Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial

Arthritis and Rheumatism

Volumn 56, Issue 4, 2007, Pages 1336-1344

  Arnold, Lesley M ^a,g   Goldenberg, Don L ^b,c   Stanford, Sharon B ^a   Lalonde, Justine K ^d   Sandhu, H S ^b   Keck Jr , Paul E ^a   Welge, Jeffrey A ^a   Bishop, Fred ^a   Stanford, Kevin E ^a   Hess, Evelyn V ^a   Hudson, James I ^e,f  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NEWTON WELLESLEY HOSPITAL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ASTRAZENECA   (United Kingdom)

^e MCLEAN HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; PLACEBO;

ADULT; AMBLYOPIA; ANXIETY; ARTICLE; ASTHENIA; BRIEF PAIN INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; FLATULENCE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEDICAL OUTCOMES STUDY SLEEP PROBLEMS INDEX; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; PATIENT GLOBAL IMPRESSION OF IMPROVEMENT; PHARYNGITIS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEDATION; SHORT FORM 36; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

AMINES; ANALGESICS; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34247230557     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22457     Document Type: Article

References (43)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
2. Hudson JI, Pope HG Jr. The relationship between fibromyalgia and major depressive disorder [review]. Rheum Dis Clin North Am 1996;22:285-303.
3. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
4. Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum 1997;40:1928-39.
5. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 1997;13:189-96.
6. Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia [review]. Mayo Clin Proc 1999;74:385-98.
7. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain [review]. Curr Rheumatol Rep 2002;4:299-305.
8. Baranauskas G, Nistri A. Sensitization of pain pathways in the spinal cord: cellular mechanisms [review]. Prog Neurobiol 1998;54:349-65.
9. Rowbotham MC. Is fibromyalgia a neuropathic pain syndrome? [review]. J Rheumatol Suppl 2005;75:38-40.
10. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management [review]. Ann Intern Med 2004;140:441-51.
11. Crofford LJ. The relationship of fibromyalgia to neuropathic pain syndromes [review]. J Rheumatol Suppl 2005;75:41-5.
12. Pan HL, Eisenach JC, Chen SR. Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther 1999;288:1026-30.
13. Hao JX, Xu XJ, Urban L, Wiesenfeld-Hallin Z. Repeated administration of systemic gabapentin alleviates allodynia-like behaviors in spinally injured rats. Neurosci Lett 2000;280:211-4.
14. Abdi S, Lee DH, Chung JM. The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg 1998;87:1360-6.
15. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology [review]. Epilepsy Res 1998;29:233-49.
16. Urban MO, Ren K, Park KT, Campbell B, Anker N, Stearns B, et al. Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. J Pharmacol Exp Ther 2005;313:1209-16.
17. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-6.
18. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999;159:1931-7.
19. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-42.
20. Rice AS, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94:215-24.
21. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119-28.
22. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials [review]. Clin Ther 2003;25:81-104.
23. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19:341-8.
24. Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000;20:467-71.
25. Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, Mascha E, Dinner D, Morris HH. Gabapentin increases slow-wave sleep in normal adults. Epilepsia 2002;43:1493-7.
26. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory [review]. Ann Acad Med Singapore 1994;23:129-38.
27. Fisher LD, Dixon DO, Herson J, Frankowski RK, Hearron MS, Peace KE. Intention to treat in clinical trials. In: Peace KE, editor. Statistical issues in drug research and development. New York: Marcel Dekker; 1990. p. 331-50.
28. Ware JH. Interpreting incomplete data in studies of diet and weight loss. N Engl J Med 2003;348:2136-7.
29. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18:728-33.
30. Fischer AA. Pressure threshold meter: its use for quantification of tender spots. Arch Phys Med Rehabil 1986;67:836-8.
31. Guy W. ECDEU assessment manual for psychopharmacology, revised. US Department of Health, Education, and Welfare publication (ADM). Rockville (MD): National Institute of Mental Health; 1976. p. 76-338.
32. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE, editors. Measuring functioning and well-being. Durham (NC): Duke University Press; 1992. p. 232-59.
33. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
34. Ware JE, Snow KK, Kosinski M, Gandek B: SF-36 health survey manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
35. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 [review]. J Clin Psychiatry 1998;59 Suppl 20:22-33.
36. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Association; 1994.
37. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002;112:191-7.
38. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data: application to the NIMH Treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 1993;50:739-50.
39. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. Hoboken (NJ): John Wiley & Sons; 2004.
40. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58.
41. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics 2000;41:104-13.
42. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15.
43. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al, for the Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-73.